[Tuberculosis and COVID-19 coinfection]

Tuberculosis is a chronic infectious disease endemic in Argentina most often localized in the lungs, caused by Mycobacterium tuberculosis. It usually afflicts poor population groups and has a significant impact on public health. COVID-19 is an acute viral disease caused by SARS-CoV-2 presenting with a typical respiratory localization, which eventually displays clinical and radiological similarities with pulmonary tuberculosis. Both entities can have a fatal outcome if they are not diagnosed and treated on time. We present a case series where pulmonary tuberculosis and COVID-19 were diagnosed simultaneously.

Hematology oncology COllaborativeVIDeoconferencing (COVID) Learning Initiative: A multi-institutional trainee alliance to rapidly disseminateemerging SARS-CoV2 and cancer best practices

Introduction: The SARS-CoV2 pandemic impacted numerous aspects of medical practice, including continuingmedical education. In-person and single-institution educational formats could not address the challenges of socialdistancing, heterogeneous regional experiences, and continuously emerging data. The vulnerability of cancerpatients to SARS-CoV2 added further urgency to overcoming these barriers. To fulfill these unmet educational andpatient care needs, we established a novel cross-institutional trainee-driven, on-line collaborative for the purpose ofgenerating multidisciplinary seminars on emerging best practices for the acute management of patients with SARS-CoV2. Methods: The COVID Learning Initiative is currently managed by clinical trainees and faculty from 13 institutionsacross 10 states. Weekly Zoom conferences were led by a rotating team consisting of 2-3 fellows overseen by 4-5expert faculty from throughout the country. Format consisted of two 15-minute instructional segments presented bytrainees, followed by a concluding 30-minute faculty Q&A panel moderated by a trainee. Attendees completedbaseline demographics, SARS-CoV2 experience surveys, and pre/post conference knowledge questions.Conferences were recorded and archived to enhance access and dissemination of knowledge. Results: Within 6 weeks and beginning just 2 weeks after inception we produced five 1-hour-longmultidisciplinary video conferences covering emerging antiviral therapies, coagulopathy, pulmonary complications, provider resilience, and ethics of resource scarcity. On average, there were 100 participants per seminar. Post-conference questioning consistently demonstrated acquisition of knowledge across topics and disciplines. Attendeesalso improved in their self-assessed comfort managing multidisciplinary aspects of SARS-CoV2. Overall, presentingcollaborations involved 11 fellows and 28 faculty representing 6 medical specialties and 17 institutions. Severalcollaborations persisted, resulting in further dissemination of knowledge with tangible outcomes such as generationof peer-reviewed manuscripts. Conclusions: The COVID Learning Initiative demonstrated a novel continuing medical education platform capableof rapidly disseminating knowledge at a national scale, while realizing new opportunities for remote traineementoring and skills development. With initial feasibility and continued interest among participating institutions, COVID Learning Initiative plans to evolve to Fellows ACHIEVE: Alliance for Collaborative Hematology OncologyInter-Institutional Education through Videoconferencing to conduct an extended multi-institutional educational serieson adapting cancer management and training program best practices.

[Simultaneous diagnosis and favorable evolution of infection with Pneumocystis jirovecii, SARS-CoV-2 and advanced HIV]

SARS-CoV-2 causes the disease named COVID-19, which emerged in Wuhan, China, in December 2019 and developed into the current pandemic. The manifestations of SARS-CoV-2 infection are highly variable. The worst outcomes are usually associated with advanced age and known risk factors. Among these, it would be reasonable to consider conditions compromising the immune system, particularly the immunodeficiency associated to HIV. To date, however, there is no evidence of HIV infection worsening the evolution and prognosis of COVID-19. Pneumocystis jirovecii (previously-P. carinii) pneumonia, is a fungal disease that most commonly affects immunocompromised persons and can be life-threatening. Typically, patients at risk are those with any underlying condition altering host immunity. We present the case of a middle-aged woman with Raynaud's syndrome who was admitted with pneumonia. During hospitalization she was simultaneously diagnosed with infection by HIV, COVID-19 and P. jirovecci. The patient evolved favorably upon empirical treatment without requiring invasive maneuvers or ventilatory support. Outpatient follow-up after hospital discharge was uneventful.